Loading clinical trials...
Loading clinical trials...
The study consists of 2 parts: Part A is a randomized, multiple-dose, double-blind, placebo-controlled sequential dose escalation study to evaluate GS-6624 in subjects with Idiopathic Pulmonary Fibros...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Gilead Sciences
NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
NCT07299695 · Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT07466420 · Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF), and more
NCT06241560 · Idiopathic Pulmonary Fibrosis
NCT05674994 · Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Arizona Pulmonary Specialists
Scottsdale, Arizona
David Geffen School of Medicine at UCLA
Los Angeles, California
Stanford University Medical Center
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions